MacLaughlin DT - Search Results

1

The role of Müllerian inhibiting substance in the evaluation of phenotypic female patients with mild degrees of virilization.

Misra M, MacLaughlin DT, Donahoe PK, Lee MM. Misra M, et al. Among authors: maclaughlin dt. J Clin Endocrinol Metab. 2003 Feb;88(2):787-92. doi: 10.1210/jc.2002-020889. J Clin Endocrinol Metab. 2003. PMID: 12574214

2

New approaches for high-yield purification of Müllerian inhibiting substance improve its bioactivity.

Lorenzo HK, Teixeira J, Pahlavan N, Laurich VM, Donahoe PK, MacLaughlin DT. Lorenzo HK, et al. Among authors: maclaughlin dt. J Chromatogr B Analyt Technol Biomed Life Sci. 2002 Jan 5;766(1):89-98. doi: 10.1016/s0378-4347(01)00436-4. J Chromatogr B Analyt Technol Biomed Life Sci. 2002. PMID: 11820299

3

Measurement of Mullerian inhibiting substance facilitates management of boys with microphallus and cryptorchidism.

Misra M, MacLaughlin DT, Donahoe PK, Lee MM. Misra M, et al. Among authors: maclaughlin dt. J Clin Endocrinol Metab. 2002 Aug;87(8):3598-602. doi: 10.1210/jcem.87.8.8742. J Clin Endocrinol Metab. 2002. PMID: 12161481

4

Highly purified müllerian inhibiting substance inhibits human ovarian cancer in vivo.

Stephen AE, Pearsall LA, Christian BP, Donahoe PK, Vacanti JP, MacLaughlin DT. Stephen AE, et al. Among authors: maclaughlin dt. Clin Cancer Res. 2002 Aug;8(8):2640-6. Clin Cancer Res. 2002. PMID: 12171896

5

Mullerian inhibiting substance: an update.

MacLaughlin DT, Donahoe PK. MacLaughlin DT, et al. Adv Exp Med Biol. 2002;511:25-38; discussion 38-40. doi: 10.1007/978-1-4615-0621-8_3. Adv Exp Med Biol. 2002. PMID: 12575754 Review.

6

Enhanced purification and production of Müllerian inhibiting substance for therapeutic applications.

Donahoe PK, Clarke T, Teixeira J, Maheswaran S, MacLaughlin DT. Donahoe PK, et al. Among authors: maclaughlin dt. Mol Cell Endocrinol. 2003 Dec 15;211(1-2):37-42. doi: 10.1016/j.mce.2003.09.009. Mol Cell Endocrinol. 2003. PMID: 14656474 Review.

7

MIS/AMH in the assessment of cryptorchidism and intersex conditions.

Lee MM, Misra M, Donahoe PK, MacLaughlin DT. Lee MM, et al. Among authors: maclaughlin dt. Mol Cell Endocrinol. 2003 Dec 15;211(1-2):91-8. doi: 10.1016/j.mce.2003.09.014. Mol Cell Endocrinol. 2003. PMID: 14656481 Review.

8

Endometrial cancer is a receptor-mediated target for Mullerian Inhibiting Substance.

Renaud EJ, MacLaughlin DT, Oliva E, Rueda BR, Donahoe PK. Renaud EJ, et al. Among authors: maclaughlin dt. Proc Natl Acad Sci U S A. 2005 Jan 4;102(1):111-6. doi: 10.1073/pnas.0407772101. Epub 2004 Dec 23. Proc Natl Acad Sci U S A. 2005. PMID: 15618407 Free PMC article.

9

Müllerian inhibiting substance regulates its receptor/SMAD signaling and causes mesenchymal transition of the coelomic epithelial cells early in Müllerian duct regression.

Zhan Y, Fujino A, MacLaughlin DT, Manganaro TF, Szotek PP, Arango NA, Teixeira J, Donahoe PK. Zhan Y, et al. Among authors: maclaughlin dt. Development. 2006 Jun;133(12):2359-69. doi: 10.1242/dev.02383. Epub 2006 May 10. Development. 2006. PMID: 16687449

10

Müllerian inhibiting substance/anti-Müllerian hormone: a potential therapeutic agent for human ovarian and other cancers.

MacLaughlin DT, Donahoe PK. MacLaughlin DT, et al. Future Oncol. 2010 Mar;6(3):391-405. doi: 10.2217/fon.09.172. Future Oncol. 2010. PMID: 20222796 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

124 results

Search Page

Filters